Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.69 |
| ▸ | HTR1A | P08908 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 3/20 | 0.62 |
| ▸ | HTR2C | P28335 | 3/20 | 0.62 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16208335 | 0.94 | HTR2A (0.66) | SIGMAR1HTR1AHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL16197598 | 0.93 | HTR2A (0.64) | SIGMAR1HTR1AHTR2AHTR2C | |
| SCHEMBL16197529 | 0.89 | HTR1A (0.67) | SIGMAR1HTR1AHTR2AHTR2CDRD3 | |
| SCHEMBL16197672 | 0.86 | SIGMAR1 (0.67) | SIGMAR1HTR1AHTR2AHTR2CDRD3 | |
| SCHEMBL16197586 | 0.85 | HTR1A (0.63) | SIGMAR1HTR1AHTR2AHTR2CDRD3 | |
| SCHEMBL16197534 | 0.84 | SIGMAR1 (0.62) | SIGMAR1HTR1AHTR2AHTR2CDRD3 | |
| SCHEMBL16197437 | 0.83 | SIGMAR1 (0.65) | SIGMAR1HTR1AHTR2AHTR2CDRD3 | |
| SCHEMBL16208332 | 0.83 | SIGMAR1 (0.65) | SIGMAR1HTR1AHTR2AHTR2CDRD3 | |
| Hydrochloric Acid SCHEMBL16197337 | 0.83 | SIGMAR1 (0.61) | SIGMAR1HTR1AHTR2AHTR2CDRD3 | |
| SCHEMBL16197087 | 0.82 | SIGMAR1 (1.00) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2989105-B1 | PYRAZINO[1,2-A]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE PHARMACEUTICALS SA (ES) | 2020-03-11 | — | — | EP | claimed |
| US-9879015-B2 | Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-01-30 | — | — | US | claimed |
| US-20160060268-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-03-03 | — | — | US | claimed |
| EP-2989105-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-03-02 | — | — | EP | claimed |
| WO-2014173903-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-10-30 | — | — | WO | claimed |
| EP-2989105-B1 | PYRAZINO[1,2-A]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE PHARMACEUTICALS SA (ES) | 2020-03-11 | — | — | EP | disclosed |
| US-9879015-B2 | Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-01-30 | — | — | US | disclosed |
| US-9879015-B2 | Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-01-30 | — | — | US | disclosed |
| US-9879015-B2 | Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-01-30 | — | — | US | disclosed |
| US-20160060268-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-03-03 | — | — | US | disclosed |
| US-20160060268-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-03-03 | — | — | US | disclosed |
| US-20160060268-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-03-03 | — | — | US | disclosed |
| EP-2989105-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-03-02 | — | — | EP | disclosed |
| WO-2014173903-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014173903-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060268-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | IDO1, TPH1, IDO2 | SIGMAR1 168/4885HTR1A 13/4885HTR2A 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.